Compare Merck & Co., Inc. (MRK) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Repligen Corporation Common Stock — how do they compare? Merck & Co., Inc. trades at $148.65 (market cap $350.29B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Merck & Co., Inc. is far larger — about 31.4× Repligen Corporation Common Stock's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Repligen Corporation Common Stock for 0 Days on average.
| MRK | RGEN | |
|---|---|---|
Market Cap | $350.29B | $11.14B |
Volume | 8,158,912 | 1,259,263 |
Sector | Health | Health |
52-Week High | $156.43 | $194.57 |
52-Week Low | $82.49 | $102.87 |
Typical Hold Time | 98 Days | 0 Days |
Enterprise Value | $397.05B | $11.02B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $147.37, up 1.32% today, with a bullish technical signal and strong institutional buying. Recent earnings beats and a $6.7 billion acquisition of Terns Pharmaceuticals highlight growth momentum. Revenue reached $65.01 billion in 2025, with net income at $18.25 billion, though the P/E ratio of 113.58 reflects high valuation expectations.
Outlook is positive with a consensus price target of $158.50, but risks include patent expirations, regulatory scrutiny, and integration challenges from acquisitions. The stock's premium valuation requires sustained earnings growth to justify further upside, with investor sentiment bolstered by analyst support and strategic pipeline expansion.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
